Moomoo AI 已提取核心信息
On February 9, 2024, Invivyd, Inc., a biopharmaceutical company based in Delaware, filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission (SEC). The registration pertains to the potential sale of up to 37,745,998 shares of common stock by selling stockholders. This includes 30,921,286 issued and outstanding shares and 6,824,712 shares issuable upon the exercise of an outstanding common stock purchase warrant. Invivyd will not sell any shares nor receive proceeds from the stockholders' sales. However, the company may receive proceeds from the exercise of the warrant, which could total approximately $23.75 million if exercised for cash. These proceeds would be used for working capital and general corporate purposes. The selling stockholders may sell the shares at market prices or negotiated transactions...Show More
On February 9, 2024, Invivyd, Inc., a biopharmaceutical company based in Delaware, filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission (SEC). The registration pertains to the potential sale of up to 37,745,998 shares of common stock by selling stockholders. This includes 30,921,286 issued and outstanding shares and 6,824,712 shares issuable upon the exercise of an outstanding common stock purchase warrant. Invivyd will not sell any shares nor receive proceeds from the stockholders' sales. However, the company may receive proceeds from the exercise of the warrant, which could total approximately $23.75 million if exercised for cash. These proceeds would be used for working capital and general corporate purposes. The selling stockholders may sell the shares at market prices or negotiated transactions, and the sales may be made on the Nasdaq Global Market, where Invivyd's stock trades under the ticker symbol 'IVVD'. The last reported sale price of Invivyd's common stock was $5.04 per share as of February 8, 2024. Invivyd is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.
2024年2月9日，总部位于特拉华州的生物制药公司Invivyd, Inc. 向美国证券交易委员会 (SEC) 提交了S-3表格注册声明。该注册涉及出售股东可能出售多达37,745,998股普通股。这包括30,921,286股已发行和流通股票，以及行使未偿还普通股购买权证后可发行的6,824,712股股票。Invivyd不会出售任何股票，也不会从股东的销售中获得收益。但是，该公司可能会从行使认股权证中获得收益，如果以现金形式行使，总额可能约为2375万美元。这些收益将用于营运资金和一般公司用途。卖出的股东可以按市场价格或协议交易出售股票，并且可以在纳斯达克全球市场上进行销售，Invivyd的股票交易代码为'IVVD'。截至2024年2月8日，Invivyd上次公布的普通股销售价格为每股5.04美元。Invivyd 被认定为 “新兴成长型公司”，上市公司报告要求有所降低。
2024年2月9日，总部位于特拉华州的生物制药公司Invivyd, Inc. 向美国证券交易委员会 (SEC) 提交了S-3表格注册声明。该注册涉及出售股东可能出售多达37,745,998股普通股。这包括30,921,286股已发行和流通股票，以及行使未偿还普通股购买权证后可发行的6,824,712股股票。Invivyd不会出售任何股票，也不会从股东的销售中获得收益。但是，该公司可能会从行使认股权证中获得收益，如果以现金形式行使，总额可能约为2375万美元。这些收益将用于营运资金和一般公司用途。卖出的股东可以按市场价格或协议交易出售股票，并且可以在纳斯达克全球市场上进行销售，Invivyd的股票交易代码为'IVVD'。截至2024年2月8日，Invivyd上次公布的普通股销售价格为每股5.04美元。Invivyd 被认定为 “新兴成长型公司”，上市公司报告要求有所降低。
有用
没用